m
Recent Posts
Connect with:
Thursday / November 19.
HomeminewsJ&J’s $2.2B Deal for Biotech

J&J’s $2.2B Deal for Biotech

Johnson & Johnson has paid US$2.2 billion to acquire Ollin Biosciences, setting up a challenge to Roche’s Vabysmo. 

With this agreement, Johnson & Johnson adds OLN324 to its pipeline. OLN324 is an investigational bispecific antibody designed to target two key pathways in retinal diseases: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). 

The drug candidate hits the same targets as Vabysmo, and is aimed at treating retinal vascular diseases, including neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). 

Johnson & Johnson announced the definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments up to approximately $1.125 billion. 

Johnson & Johnson will also enter into a separate development funding agreement with Blackstone Life Sciences to support the Phase 3 clinical advancement of OLN324, contingent upon acquisition close. Blackstone will pay a total of $750 million to Johnson & Johnson over multiple years to fully fund the Phase 3 development of OLN324. 

In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments as well as single digit royalties. 

“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control,” said Kip Connor, Vice President, Ophthalmology Disease Area Stronghold Leader, Johnson & Johnson.  

“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control” 

“The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients.”

DECLARATION

DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.